National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Ga.
Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga.
Acad Pediatr. 2018 Mar;18(2S):S3-S10. doi: 10.1016/j.acap.2017.09.014.
Since human papillomavirus (HPV) vaccine was first introduced for females in the United States in 2006, vaccination policy has evolved as additional HPV vaccines were licensed and new data became available. The United States adopted a gender neutral routine HPV immunization policy in 2011, the first country to do so. Vaccination coverage is increasing, although it remains lower than for other vaccines recommended for adolescents. There are various reasons for low coverage, and efforts are ongoing to increase vaccine uptake. The safety profile of HPV vaccine has been well established from 10 years of postlicensure monitoring. Despite low coverage, the early effects of the HPV vaccination program have exceeded expectations.
自 2006 年美国首次为女性引进人乳头瘤病毒(HPV)疫苗以来,随着更多 HPV 疫苗获得许可和新数据的出现,疫苗接种政策也在不断发展。美国于 2011 年采取了性别中立的常规 HPV 免疫接种政策,成为首个采取这一政策的国家。疫苗接种覆盖率正在上升,但仍低于其他推荐给青少年的疫苗。覆盖率低的原因有很多,目前正在努力提高疫苗接种率。HPV 疫苗的安全性在上市后监测的 10 年中得到了充分证实。尽管覆盖率较低,但 HPV 疫苗接种计划的早期效果超出了预期。